OPCH — Option Care Health, Inc.

Summary of Option Care Health (OPCH) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $1.43 billion, representing a 12% increase year-over-year.
• Gross Profit: $273 million, up 6.3% from last year, impacted by therapy mix and lower-margin products.
• Adjusted EBITDA: $119.5 million, a 3.4% increase, with an adjusted EBITDA margin of 8.3%.
• Adjusted EPS: $0.45, reflecting a 9.8% growth, aided by share repurchases and a lower tax rate.
• Cash Flow: Year-to-date cash flow from operations reached $223 million.
• Net Debt to Adjusted EBITDA: 1.9x at the end of Q3.

2. Strategic Updates and Business Highlights

• Leadership Changes: Meenal Sethna joined as CFO, succeeding Mike Shapiro, who transitioned to a strategic adviser role.
• Therapy Growth: Acute therapy grew in the mid-teens, while chronic therapy saw low double-digit growth, despite a 380 basis point negative impact from the adoption of Stelara biosimilars.
• Expansion Initiatives: Increased utilization of bed day management programs and site of care initiatives, enhancing partnerships with payers and pharma manufacturers.
• Nursing Visits: Conducted over 175,000 nursing visits, with 34% in infusion suites, and over 55,000 visits by Naven Health.
• Technology Investments: Launched three new applications aimed at improving patient onboarding and operational efficiency.

3. Forward Guidance and Outlook

• Revised Full-Year Guidance:
  • Revenue expected between $5.6 billion and $5.65 billion.
  • Adjusted EBITDA projected at $468 million to $473 million.
  • Adjusted EPS forecasted between $1.68 and $1.72.
• Cash Flow: Anticipated to exceed $320 million for the year.
• Market Position: Confident in the ability to navigate regulatory changes and competitive pressures while continuing to grow.

4. Bad News, Challenges, or Points of Concern

• Stelara Biosimilar Impact: The transition to Stelara biosimilars is expected to continue affecting revenue and gross profit margins, with an anticipated headwind of approximately $70 million for 2025.
• G&A Expenses: General and administrative expenses rose by 10% year-over-year, influenced by the Intramed acquisition and increased variable compensation.
• Competitive Landscape: While the exit of a significant competitor has provided growth opportunities, ongoing competitive pressures remain a concern.

5. Notable Q&A Insights

• Stelara Uptake: Management indicated that the uptake of Stelara biosimilars is expected to continue impacting revenue and gross profit, with ongoing monitoring of the situation.
• M&A Strategy: The company is actively exploring tuck-in acquisitions and near adjacencies but remains disciplined in capital deployment, prioritizing internal investments and organic growth.
• Site of Care Initiatives: There is increasing receptivity among health plans regarding site of care initiatives, which are seen as beneficial for managing total care costs.
• Advanced Practitioner Model: Currently, 24 out of 175 infusion facilities are equipped for advanced practitioner services, with plans for continued expansion.

Overall, Option Care Health reported solid growth in Q3 2025, with strategic initiatives aimed at enhancing service delivery and operational efficiency, despite facing challenges related to biosimilar competition and rising administrative costs. The company remains optimistic about its growth trajectory moving into 2026.